Corrigendum to "Δ9-Tetrahydrocannabinol regulates the p53 post-translational modifiers Murine double minute 2 and the Small Ubiquitin MOdifier protein in the rat brain" [FEBS Lett. 583 (2009) 3412-3418] (DOI:10.1016/j.febslet.2009.09.056);Δ9-Tetrahydrocannabinol regulates the p53 post-translational modifiers Murine double minute 2 and the Small Ubiquitin MOdifier protein in the rat brain

FEBS Letters

Volumn 583, Issue 21, 2009, Pages 3412-3418

  Gowran, Aoife ^a   Murphy, Carrie E ^a   Campbell, Veronica A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cannabinoid; Murine double minute; Post translational modification; Signal transduction; Small Ubquitin like MOdifier

Indexed keywords

CANNABINOID 1 RECEPTOR; DRONABINOL; PROTEIN MDM2; PROTEIN P53; SUMO 1 PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; COMPUTER MODEL; CONTROLLED STUDY; DOUBLE MINUTE CHROMOSOME; IMMUNOCYTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROCESSING; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SUMOYLATION;

CANNABIS; MURINAE; RATTUS;

ANIMALS; BRAIN; GENE EXPRESSION REGULATION; MICE; NEURONS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; RECEPTOR, CANNABINOID, CB1; SUMO-1 PROTEIN; TETRAHYDROCANNABINOL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350329246     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.11.015     Document Type: Erratum

References (44)

1. Ashton C.H. Adverse effects of cannabis and cannabinoids. Br. J. Anaesth. 83 (1999) 637-649
2. Mechoulam R., and Gaoni Y. A total synthesis of Dl-Delta-1 Tetrahydrocannabinol, the active constituent of Hashish. J. Am. Chem. Soc. 87 (1965) 3273-3275
3. Paton W.D., and Pertwee R.G. Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br. J. Pharmacol. 44 (1972) 250-261
4. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., and Porrino L.J. Cannabinoid physiology and pharmacology 30 years of progress. Neuropharmacology 47 Suppl. 1 (2004) 345-358
5. Sarne Y., and Keren O. Are cannabinoid drugs neurotoxic or neuroprotective?. Med. Hypotheses 63 (2004) 187-192
6. Chan G.C., Hinds T.R., Impey S., and Storm D.R. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J. Neurosci. 18 (1998) 5322-5332
7. Downer E.J., Gowran A., Murphy A.C., and Campbell V.A. The tumour suppressor protein, p53, is involved in the activation of the apoptotic cascade by Delta9-tetrahydrocannabinol in cultured cortical neurons. Eur. J. Pharmacol. 564 (2007) 57-65
8. Gowran A., and Campbell V.A. A role for p53 in the regulation of lysosomal permeability by 9-tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration. J. Neurochem. 105 (2008) 1513-1524
9. Sanchez C., Galve-Roperh I., Canova C., Brachet P., and Guzman M. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436 (1998) 6-10
10. Downer E.J., Gowran A., and Campbell V.A. A comparison of the apoptotic effect of Delta(9)-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Res. 1175 (2007) 39-47
11. Chen J., Lee C.T., Errico S.L., Becker K.G., and Freed W.J. Increases in expression of 14-3-3 eta and 14-3-3 zeta transcripts during neuroprotection induced by delta9-tetrahydrocannabinol in AF5 cells. J. Neurosci. Res. 8 (2007) 1724-1733
12. Lane D.P. Cancer. p53, guardian of the genome. Nature 358 (1992) 15-16
13. Lecine A.J. P53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
14. Lavin M.F., and Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 13 (2006) 941-950
15. Giaccia A.J., and Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12 (1998) 2973-2983
16. Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268 (2001) 2764-2772
17. Shieh S.Y., Ikeda M., Taya Y., and Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91 (1997) 325-334
18. Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., Scheffner M., and Del Sal G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18 (1999) 6462-6471
19. Rodriguez M.S., Desterro J.M., Lain S., Midgley C.A., Lane D.P., and Hay R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18 (1999) 6455-6461
20. Johnson E.S. Protein modification by SUMO. Annu. Rev. Biochem. 73 (2004) 355-382
21. Melchoir F., and Hengst L. SUMO-1 and p53. Cell Cycle 1 (2002) 245-249
22. Carter S., Bischof O., Dejean A., and Vousden K.H. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9 (2007) 428-435
23. Matunis M.J., Coutavas E., and Blobel G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 135 (1996) 1457-1470
24. Johnson E.S., and Blobel G. Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins. J. Cell Biol. 147 (1999) 981-994
25. Scheschonka A., Tang Z., and Betz H. Sumoylation in neurons: nuclear and synaptic roles?. Trends Neurosci. 3 (2007) 85-91
26. Martin S., Nishimune A., Mellor J.R., and Henley J.M. SUMOylation regulates kainate-receptor-mediated synaptic transmission. Nature 447 (2007) 321-325
27. Guzman M., Sanchez C., and Galve-Roperh I. Cannabinoids and cell fate. Pharmacol. Ther. 95 (2002) 175-184
28. Hashimotodani Y., Ohno-Shosaku T., and Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 2 (2007) 127-137
29. Gately S.J., Gifford A.N., Volkow N.D., Lan R., and Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 307 (1996) 331-338
30. Hilgarth R.S., and Sarge K.D. Detection of Sumoylated proteins. In: Paytterson C., and Cyr D.M. (Eds). Methods in Molecular Biology, Ubiquitin-Proteasome protocols (2005), Humana Press Inc., New York, NY 329-337
31. Ren J., Gao X., Jin C., Zhu M., Wang X., Shaw A., Wen L., Yao X., and Xue Y. Systematic study of protein sumoylation: development of a site-specific predictor of SUMOsp 2.0. Proteomics 9 (2009) 3409-3412
32. Iwakuma T., and Lozano G. MDM2, an introduction. Mol. Cancer Res. 1 (2003) 993-1000
33. Perry M.E., Mendrysa S.M., Saucedo L.J., Tannous P., and Holubar M. P76(MDM2) inhibits the ability of p90(MDM2) to destabilize p53. J. Biol. Chem. 275 (2000) 5733-5738
34. Pochampally R., Fodera B., Chen L., Lu W., and Chen J. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J. Biol. Chem. 274 (1999) 15271-15277
35. Pochampally R., Fodera B., Chen L., Shao W., Levine E.A., and Chen J. A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene 17 (1998) 2629-2636
36. Muller S., Berger M., Lehembre F., Seeler J.S., Haupt Y., and Dejean A. C-Jun and p53 activity is modulated by SUMO-1 modification. J. Biol. Chem. 275 (2000) 13321-13329
37. Watson I.R., and Irwin M.S. Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 8 (2006) 655-666
38. Bossis G., and Melchoir F. SUMO: regulating the regulator. Cell Div. 1 (2006) 13
39. Lin J.Y., Ohshima T., and Shimotohno K. Association of Ubc9, an E2 ligase for SUMO conjugation, with p53 is regulated by phosphorylation of p53. FEBS Lett. 573 (2004) 15-18
40. Boddy M.N., Howe K., Etkin L.D., Solomon E., and Freemont P.S. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13 (1996) 971-982
41. Desterro J.M., Rodriguez M.S., and Hay R.T. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell 2 (1998) 233-239
42. Okura T., Gong L., Kamitani T., Wada T., Okura I., Wei C.F., Chang H.M., and Yeh E.T. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 157 (1996) 4277-4281
43. Shalizi A., Bilimoria P.M., Stegmüller J., Gaudillière B., Yang Y., Shuai K., and Bonni A. PIASx is a MEF2 SUMO E3 ligase that promotes postsynaptic dendritic morphogenesis. J. Neurosci. 37 (2007) 10037-10046
44. Gibb S.L., Boston-Howes W., Lavina S.Z., Gustincich S., Brown Jr. R.H., Pasinelli P., and Trotti D. A caspase-3 cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1 linked ALS. J. Biol. Chem. 44 (2007) 32480-32490